The following Structured Product Label (SPL) was submitted to the FDA by Bispit Canada Ltd. for the product Gout Relief 3310-s (NDC 85631-006). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.
This specific version of the label includes detailed information regarding otc - active ingredient, inactive ingredient, otc - keep out of reach of children, dosage & administration, indications & usage, other safety information, warnings, otc - purpose, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.
MEDICAGO SATIVA WHOLE 20.00%
CHICORY ROOT 23.00%
GLUCOSAMINE HYDROCHLORIDE 10.00%
BUCKWHEAT 7.00%
TEA LEAF 5.00%
MORUS ALBA LEAF 13.00%
LICORICE 0.20%
FU LING 2.00%
COIX LACRYMA-JOBI SEED 8.00%
This product has a significanteffect on gout, crystal deposits,and hyperuricemia;
elt has an auxiliary effectof mitigating kidney stonesand bladder stones
Keep out of reach of children
The product has great somatosensation after taking it atleast 21 days in the earty stage;3. Elevated uric acid or gout recurrence and site changes arenoral in the earty stage of taking this product;
Dissolved CrystallizationKidney StoneGallstone< Urinary Calculus
Do not use if seal is broken.
Do not eat freshness packet enclosed.
Keep out of direct sunlight, high temperature, and humidity.
Store in a cool, dry place.
For your health, please read the followingcarefully
1. The use of three vials can effectivety dissolve crystallization (ittakes time to dissolve crystallization);2. The product has great somatosensation after taking it atleast 21 days in the early stage;3. Elevated uric acid or gout recurrence and site changes arenormal in the early stage of taking this product;4. Try not to drink alcohol or drink less 15 days before takingthis product;
5. This product certainly has significant effect on gout,crystallization and hyperuricemia;
This product has a significanteffect on gout, crystal deposits,and hyperuricemia; elt has an auxiliary effectof mitigating kidney stonesand bladder stones
Labeling (85631 006 01)
* Please review the disclaimer below.
